Research
Our published research:
Highlighted
Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity
Blood
·
12 Jan 2023
·
doi:10.1182/blood.2022018258
All
2024
Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia
Science Translational Medicine
·
12 Jun 2024
·
doi:10.1126/scitranslmed.adi5336
Inhibition of mitochondrial folate metabolism drives differentiation through mTORC1 mediated purine sensing
Nature Communications
·
02 Mar 2024
·
doi:10.1038/s41467-024-46114-0
Leukaemia exposure alters the transcriptional profile and function of BCR::ABL1 negative macrophages in the bone marrow niche
Nature Communications
·
05 Feb 2024
·
doi:10.1038/s41467-024-45471-0
2023
Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells
Nature Communications
·
17 Aug 2023
·
doi:10.1038/s41467-023-40222-z
Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells
EMBO reports
·
25 Jul 2023
·
doi:10.15252/embr.202256279
Unraveling Heterogeneity in the Aging Hematopoietic Stem Cell Compartment: An Insight From Single-cell Approaches
HemaSphere
·
26 May 2023
·
doi:10.1097/hs9.0000000000000895
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death
Nature Communications
·
14 Apr 2023
·
doi:10.1038/s41467-023-37652-0
Metabolism in stem cell driven leukaemia: parallels between haematopoiesis and immunity
Blood
·
12 Jan 2023
·
doi:10.1182/blood.2022018258
2022
Mitochondrial folate metabolism inhibition drives differentiation through mTORC1 mediated purine sensing
Cold Spring Harbor Laboratory
·
21 Dec 2022
·
doi:10.1101/2022.12.21.521404
BH3 mimetics in combination with nilotinib or ponatinib represent a promising therapeutic strategy in blast phase chronic myeloid leukemia
Cell Death Discovery
·
15 Nov 2022
·
doi:10.1038/s41420-022-01211-1
E2F1 induction folowing DNA-damage and oncogene activation.
[no publisher info]
·
27 May 2022
·
[no id info]
E2F1 induction following DNA damage and oncogene activation.
[no publisher info]
·
27 May 2022
·
[no id info]
Targeting ULK1 in cancer stem cells: insight from chronic myeloid leukemia
Autophagy
·
01 Mar 2022
·
doi:10.1080/15548627.2022.2041152
2021
ULK1 inhibition promotes oxidative stress–induced differentiation and sensitizes leukemic stem cells to targeted therapy
Science Translational Medicine
·
29 Sep 2021
·
doi:10.1126/scitranslmed.abd5016
Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia
Leukemia
·
24 Sep 2021
·
doi:10.1038/s41375-021-01416-w
Folate metabolism: a re-emerging therapeutic target in haematological cancers
Leukemia
·
11 Mar 2021
·
doi:10.1038/s41375-021-01189-2
2020
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
Leukemia
·
10 Jan 2020
·
doi:10.1038/s41375-019-0700-9
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Nature Reviews Cancer
·
06 Jan 2020
·
doi:10.1038/s41568-019-0230-9
2019
Utilizing Stimulated Raman Scattering Microscopy To Study Intracellular Distribution of Label-Free Ponatinib in Live Cells
Journal of Medicinal Chemistry
·
12 Dec 2019
·
doi:10.1021/acs.jmedchem.9b01546
BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia
Leukemia
·
28 Aug 2019
·
doi:10.1038/s41375-019-0557-y
2018
Autophagy and mitochondrial metabolism: insights into their role and therapeutic potential in chronic myeloid leukaemia
The FEBS Journal
·
08 Oct 2018
·
doi:10.1111/febs.14659
The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought
Frontiers in Cell and Developmental Biology
·
26 Sep 2018
·
doi:10.3389/fcell.2018.00120
Targeting quiescent leukemic stem cells using second generation autophagy inhibitors
Leukemia
·
05 Sep 2018
·
doi:10.1038/s41375-018-0252-4
hsa-mir183/EGR1–mediated regulation of E2F1 is required for CML stem/progenitor cell survival
Blood
·
05 Apr 2018
·
doi:10.1182/blood-2017-05-783845
2017
Auto-Commentary on: “Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells”
Molecular & Cellular Oncology
·
18 Dec 2017
·
doi:10.1080/23723556.2017.1403532
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
JNCI: Journal of the National Cancer Institute
·
20 Nov 2017
·
doi:10.1093/jnci/djx236
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Nature Medicine
·
18 Sep 2017
·
doi:10.1038/nm.4399
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor–Sensitive and -Resistant Chronic Myeloid Leukemia
Clinical Cancer Research
·
30 Apr 2017
·
doi:10.1158/1078-0432.ccr-16-1930
2016
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells
Autophagy
·
11 May 2016
·
doi:10.1080/15548627.2016.1162359
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy
·
02 Jan 2016
·
doi:10.1080/15548627.2015.1100356
2015
Mtss1 is a critical epigenetically regulated tumor suppressor in CML
Leukemia
·
01 Dec 2015
·
doi:10.1038/leu.2015.329
2014
Do we need more drugs for chronic myeloid leukemia?
Immunological Reviews
·
15 Dec 2014
·
doi:10.1111/imr.12234
The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors
Stem Cells
·
18 Aug 2014
·
doi:10.1002/stem.1748
2013
Role of autophagy in cancer prevention, development and therapy
Essays in Biochemistry
·
27 Sep 2013
·
doi:10.1042/bse0550133
Autophagy in blood cancers: biological role and therapeutic implications
Haematologica
·
01 Sep 2013
·
doi:10.3324/haematol.2012.079061
Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets
·
31 Aug 2013
·
doi:10.2174/15680096113139990088
Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
Journal of Clinical Investigation
·
01 Aug 2013
·
doi:10.1172/JCI71197
2012
Guidelines for the use and interpretation of assays for monitoring autophagy
Autophagy
·
01 Apr 2012
·
doi:10.4161/auto.19496
Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Expert Review of Anticancer Therapy
·
01 Mar 2012
·
doi:10.1586/era.12.10
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival
Blood
·
09 Feb 2012
·
doi:10.1182/blood-2010-12-326843
2011
Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML
Blood
·
25 Aug 2011
·
doi:10.1182/blood-2011-01-330621
Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?
Expert Review of Hematology
·
01 Aug 2011
·
doi:10.1586/ehm.11.34
The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
Leukemia
·
12 Apr 2011
·
doi:10.1038/leu.2011.67
2010
Oncogene-Induced Sensitization to Chemotherapy-Induced Death Requires Induction as well as Deregulation of E2F1
Cancer Research
·
12 May 2010
·
doi:10.1158/0008-5472.CAN-09-2876
Targeting Chronic Myeloid Leukemia Stem Cells
Current Hematologic Malignancy Reports
·
24 Feb 2010
·
doi:10.1007/s11899-010-0043-0
2009
Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells
Journal of Clinical Investigation
·
01 May 2009
·
doi:10.1172/jci35660
Combined BCR-ABL inhibition with lentiviral-delivered shRNA and dasatinib augments induction of apoptosis in Philadelphia-positive cells
Experimental Hematology
·
01 Feb 2009
·
doi:10.1016/j.exphem.2008.10.013